Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Liabilities and Shareholders Equity (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Liabilities and Shareholders Equity data on record, last reported at $359.1 million in Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 2.71% year-over-year to $359.1 million; the TTM value through Dec 2025 reached $1.2 billion, down 17.57%, while the annual FY2025 figure was $359.1 million, 2.71% up from the prior year.
  • Liabilities and Shareholders Equity reached $359.1 million in Q4 2025 per CCCC's latest filing, up from $265.5 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $528.4 million in Q2 2021 and bottomed at $265.5 million in Q3 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $402.2 million, with a median of $378.8 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 121.67% in 2021, then dropped 29.4% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $506.8 million in 2021, then decreased by 14.98% to $430.8 million in 2022, then dropped by 12.62% to $376.5 million in 2023, then dropped by 7.13% to $349.6 million in 2024, then increased by 2.71% to $359.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $359.1 million in Q4 2025, $265.5 million in Q3 2025, and $296.5 million in Q2 2025.